In December 2022, Johnson & Johnson acquisitions made a significant splash in the medtech industry when the company committed $16.6 billion to acquire Abiomed—a move that would mark the beginning of a high-profile series of acquisitions aimed at solidifying their position in the high-risk cardiac intervention space. This acquisition was more than just a financial transaction; it signified the company’s strategic approach to tapping into the rapidly growing cardiovascular devices market.
Johnson & Johnson has long been a dominant player in medical technologies, with a well-established presence in areas like arrhythmia management and stroke intervention. However, these recent Johnson & Johnson acquisitions are designed to expand their footprint, particularly in high-risk cardiac procedures, an area where the company sees considerable growth potential. According to LSI’s Market Intelligence team, the cardiovascular devices market is currently valued at roughly $60 billion, and it continues to grow as cardiovascular diseases remain one of the leading causes of death worldwide.
Abiomed (2022): Known for its Impella heart pump, a circulatory support system
Laminar (2023): Developer of a left atrial appendage (LAA) elimination device
Shockwave Medical (2024): Known for its intravascular lithotripsy (IVL) technology
V-Wave (2024): Focuses on innovative interatrial shunt technology for the treatment of heart failure
These acquisitions share a common goal: to tackle some of the most challenging and high-mortality conditions in cardiovascular health. With cardiovascular diseases on the rise—particularly after the COVID-19 pandemic—Johnson & Johnson acquisitions reflect the company’s growing commitment to addressing heart failure, stroke, and other life-threatening cardiovascular issues. The broader focus on these high-risk areas ensures that Johnson & Johnson is not only staying relevant but positioning itself as a key player in a fast-evolving market.
As these acquisitions continue to unfold, the market opportunities presented by these technologies are substantial. Let’s break down the potential each of these companies brings to the table.
|
Device |
Market Value (2023) |
Projected CAGR (2023-2028) |
|
Laminar’s LAA Closure Device |
$1.4 billion |
20%+ |
|
Shockwave’s IVL Technology |
$1.4 billion |
23.6% |
|
Abiomed’s Impella Pump |
$1.8 billion |
12% |
|
V-Wave’s Interatrial Shunt |
$7.0 billion |
2.5% |
In addition to these acquisitions, Johnson & Johnson is strengthening its existing position in the atrial fibrillation (AFib) market through its subsidiary, Biosense Webster, which is already a key player in the AFib space. Biosense Webster competes directly with market leader Boston Scientific, continuing to advance technologies that improve outcomes for patients with arrhythmia-related conditions.
Though V-Wave’s projected growth may appear conservative, it’s worth noting that the technology’s unique features could offer a competitive edge over existing treatments, leading to increased adoption and market share in the long run. The heart failure space, in particular, is a rapidly evolving field with high demand for new and innovative treatments.
The ongoing Johnson & Johnson acquisitions are setting the stage for the company to not only maintain its dominance in existing areas of medical technology but also to carve out a leading position in the fast-growing cardiovascular device market. These acquisitions reflect a forward-thinking strategy, with Johnson & Johnson making moves to strengthen its presence in key therapeutic areas that address some of the world’s most pressing health issues. By acquiring companies like Abiomed, Laminar, Shockwave Medical, and V-Wave, Johnson & Johnson is positioning itself for long-term success and ensuring it remains at the forefront of the medtech industry.
These strategic investments underscore the company’s commitment to addressing heart failure, stroke, and other major cardiovascular diseases, which are expected to become even more prevalent in the coming years. With these acquisitions, Johnson & Johnson is not just securing growth in the present but setting itself up to be a dominant force in the cardiovascular devices market for years to come.
New data released on global stroke and lung procedure volumes. Check out our Global Procedure Volumes Database for access.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
